文献速递造血干细胞移植与细胞治疗

芦可替尼治疗初治及激素难治性儿童急性移植物抗宿主病:REACH4研究

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study.
PubMed 文献 · Blood · 2024-01-01

REACH4是一项1/2期、开放标签、单臂、多中心研究,在45例2至4级急性移植物抗宿主病(aGVHD)初治及激素难治性儿童患者中评估芦可替尼的药代动力学、疗效和安全性。芦可替尼按年龄给药以匹配成人10 mg每日两次的暴露,各年龄组暴露相当,起始剂量确认为2期推荐剂量。第28天总缓解率为84.4%(90%CI 72.8-92.5),第56天持久总缓解率为66.7%(90%CI 53.4-78.2),各年龄组及初治和激素难治亚组均观察到高缓解率,安全性与aGVHD患者预期一致,无新安全信号。

要点

  • 芦可替尼按年龄给药(≥12至<18岁10 mg每日两次;≥6至<12岁5 mg每日两次;≥2至<6岁4 mg/m2每日两次),各年龄组暴露相当,起始剂量确认为2期推荐剂量。
  • 45例2至4级aGVHD儿童患者第28天总缓解率为84.4%(90%CI 72.8-92.5),第56天持久总缓解率为66.7%(90%CI 53.4-78.2)。
  • 各年龄组及初治和激素难治亚组均观察到高缓解率,不良事件与aGVHD患者使用芦可替尼的预期一致,无新安全信号。

核心结论

  • 在儿童aGVHD患者中,芦可替尼显示出有临床意义的疗效,且无新安全信号。

研究设计与样本

  • REACH4为1/2期、开放标签、单臂、多中心研究,纳入45例2至4级aGVHD的初治及激素难治性儿童患者。
  • 芦可替尼按年龄给药以匹配成人10 mg每日两次的暴露:1组(≥12至<18岁)10 mg每日两次,2组(≥6至<12岁)和3组(≥2至<6岁)初步起始剂量分别为5 mg每日两次和4 mg/m2每日两次。
  • 1期主要目标为评估芦可替尼药代动力学参数并为<12岁患者确定年龄适用的2期推荐剂量;2期主要目标为第28天总缓解率,关键次要目标为第56天持久总缓解率。
  • 试验注册号:NCT03491215。

主要发现

  • 芦可替尼暴露在各年龄组间相当,起始剂量确认为2期推荐剂量。
  • 芦可替尼暴露中位持续时间为3.8个月(范围0.3-11.2)。
  • 全部患者第28天总缓解率为84.4%(90%CI 72.8-92.5),第56天持久总缓解率为66.7%(90%CI 53.4-78.2)。
  • 各年龄组及初治和激素难治亚组均观察到高缓解率。
  • 不良事件与aGVHD患者使用芦可替尼的预期一致(贫血、中性粒细胞和白细胞计数降低)。

关键数值与推荐

  • 1组(≥12至<18岁)芦可替尼10 mg每日两次;2组(≥6至<12岁)5 mg每日两次;3组(≥2至<6岁)4 mg/m2每日两次;起始剂量确认为2期推荐剂量。
  • 全部患者第28天总缓解率84.4%(90%CI 72.8-92.5),第56天持久总缓解率66.7%(90%CI 53.4-78.2)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In REACH4, a phase 1/2, open-label, single-arm, multicenter study, the pharmacokinetics (PK), efficacy, and safety of ruxolitinib were evaluated in treatment-naïve and steroid-refractory pediatric patients with grade 2 to 4 acute graft-versus-host disease (aGVHD; n = 45). Ruxolitinib dosing was based on age and targeted the exposure in adults receiving 10 mg twice daily; group 1 (aged ≥12 to <18 years) received 10 mg twice daily and preliminary starting doses for groups 2 (aged ≥6 to <12 years) and 3 (aged ≥2 to <6 years) were 5 mg twice daily and 4 mg/m2 twice daily, respectively. The phase 1 primary objective was to assess ruxolitinib PK parameters and define an age-appropriate recommended phase 2 dose (RP2D) for patients aged <12 years. The phase 2 primary objective was to measure the activity of ruxolitinib as assessed by overall response rate (ORR) at day 28; the key secondary objective was to assess the durable ORR at day 56. Ruxolitinib exposure was comparable across age groups; starting doses were confirmed as the RP2D. The median duration of ruxolitinib exposure was 3.8 months (range, 0.3-11.2). ORR in all patients was 84.4% (90% confidence interval [CI], 72.8-92.5) at day 28, with a durable ORR at day 56 of 66.7% (90% CI, 53.4-78.2); high response rates were observed across age groups and in both treatment-naïve and steroid-refractory subgroups. Adverse events were consistent with those expected in patients with aGVHD (anemia, decreased neutrophil and leukocyte count) treated with ruxolitinib. In pediatric patients with aGVHD, ruxolitinib showed clinically meaningful efficacy with no new safety signals. This trial was registered at www.clinicaltrials.gov as #NCT03491215.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Locatelli F, Kang HJ, Bruno B, et al. Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study. Blood. 2024. PMID: 39046767. doi:10.1182/blood.2023022565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。